the treatment of the disease. Development of sensitive and specific rapid detection assays is of great significance for the diagnosis. Here, we describe a promising method of using gold-labeled streptavidin fusion proteins as novel signal reporter in a rapid detection assay for HCV infection. Results: M-STV showed slightly higher biotin-binding activity and similar binding specificity as compared to commercial streptavidin. The gold-labeled M-STV bound specifically to biotin moieties immobilized on the rapid test strips in a dose-responsive manner and was successfully used in detecting HCV antibodies in serum samples of patients infected with HCV. The rapid test displayed higher detection sensitivity than gold-labeled commercial NeutrAvidin.
| INTRODUC TI ON
Hepatitis C virus (HCV) infection is a serious health problem affecting roughly 2.2%-3% of the world's population. [1] [2] [3] In China, the HCV infection rate was estimated to be about 2.2%-3.7%, [3] [4] [5] but like other chronic viral infections, the majority of infected patients remain undiagnosed, partly due to the asymptomatic feature of the infection until late stages of the disease progression and partly due to the lack of resources to perform large-scale laboratory tests, especially in the rural areas in China. [6] [7] [8] As up to now there is no effective HCV vaccine available to prevent further spread of the infection, early diagnosis and systematic screen of high-risk population will have several advantages over late-stage diagnosis. Early diagnosis not only gives infected people time and opportunity to adjust their lifestyle to delay and slow down the disease progression, but also gives the doctors more therapeutic options to choose to treat the disease. 9 In addition, early diagnosis will also let people be aware of the disease and take necessary measurement to prevent further infections. 10 The routine diagnosis of HCV infection involves detecting anti-HCV antibodies in the blood, typically by enzyme-linked immunosorbent assay (ELISA), which requires laboratory equipment and trained medical technicians. Recently, lateral flow chromatographic rapid test based on HCV antigen-antibody interactions has been developed and used in point-of-care clinical testing. [11] [12] [13] [14] In these rapid tests, protein A or HCV antigens labeled with colloidal gold nanoparticles were used as detection reporters. These reporter molecules have high binding affinity and specificity toward the anti-HCV antibodies captured by the HCV antigens on the solid phase, thus ensuring high sensitivity and high specificity of the rapid test devices.
The rapid tests open a new opportunity to increase the diagnosis rate of HCV in places where more sophisticated laboratory testing is not available and where large-scale HCV screens are required.
Besides protein A and specific antigens, another molecular interaction widely used in biological detection is between streptavidin and biotin. 15, 16 The binding between streptavidin and biotin is noncovalent but has extremely high affinity, with the dissociation constant of about 10 -15 mol/L, about 10 3 -10 6 times higher than that of typical antigen-antibody interaction. 15 The biotin-streptavidin and biotin-NeutrAvidin, a deglycosylated form of avidin, 17 have also been used in rapid tests. [18] [19] [20] In this report, we describe construction of two streptavidin fusion proteins, labeling them with colloidal gold and using them in a rapid test system for HCV detection. The rapid test using the gold-labeled streptavidin fusion protein was more sensitive than using the commercial gold-labeled streptavidin products as the detection reporter.
| MATERIAL S AND ME THODS

| Constructing recombinant genes encoding streptavidin fusion proteins
The 477 bp streptavidin coding sequence (stv) without the signal peptide region (Genbank accession #: X03591) was synthesized at Sangon Biotech (Shanghai, China). 21 The stv was amplified by PCR using primer pair STV-HIS (forward, 5'-ACACCATATGGGCATCACC GGCACCTGGTA; reverse, 5'-ACAGGATCCTTAGTGGTGATGATGGT GATGCTGCTGAACGGCGTCGAGC) to introduce 6 histidine codons (HIS-tag) at the 3'-end of the gene. The stv PCR product was digested with restriction enzymes NdeI and BamHI, and cloned into expression vectors pMAL-5cx (New England Biolabs), which allowed in-frame fusion between stv and the gene encoding maltose-binding protein (MBP) on the vector. The pMAL-5cx::stv recombinant plasmid was transformed into E. coli ER2523 and selected on LB agar plates containing ampicillin (100 μg/mL).
The stv PCR product was also cloned into pET28a (Novagen, Darmstadt, Germany), and the pET28a::stv recombinant plasmid was transformed into E. coli strain DH5α by selecting on LB agar plates containing kanamycin (50 μg/mL). 
| Purification of recombinant proteins
To express recombinant streptavidin fusion proteins, cells were grown in LB at 37°C and, at OD600 = 0. and estimate the purity of the purified proteins, SDS-polyacrylamide gel electrophoresis (PAGE) was carried out on 10%-20% gradient gels.
| ELISA tests
| Binding efficiency test
Recombinant streptavidin fusion proteins as well as streptavi- The wells were emptied and washed three times with PBST. Then 100 μL of HRP goat anti-mouse IgG (BioLegend), diluted 1:1000 in 2% NFM in PBS, was added and incubated for 0.5 hours. The wells were emptied and washed three times with PBST, and 100 μL of TMB Substrate (Thermo Scientific) was added. The plate was incubated at 37°C for 10 minutes. The color development reaction was stopped by adding 50 μL of 2N HCl and A 450 was measured. Dose-responsive curves were generated after subtracting the blanks.
| Binding specificity test
Wells , and Avidin (all from Thermo Scientific), diluted to 17 nmol/L in PBS, were added to the wells and incubated for 1.5 hours.
The wells were emptied and washed three times with PBST. The biotin mouse anti-human IL-1α monoclonal antibody (1 μg/mL) was added.
The binding was allowed to proceed for 1.5 hours. The subsequent steps of washing, adding HRP Goat Anti-mouse IgG, and adding TMB Substrate for color development were the same as described in the binding efficiency test above. For each protein tested, four wells were coated and the results were averaged after subtracting the blanks.
| Preparation of colloidal gold particles and labeling of proteins
To 100 mL of triple distilled water in a beaker, 1 mL of 1% chloroauric acid (HAuCl 4 ) was added and mixed. The beaker was heated with moderate stirring until boiling, and 1.5 mL of 1% trisodium citrate was quickly added with increased stirring while the heating was continued.
When the gold nanoparticle suspension formed and gradually turned to wine-red, the heating was stopped. The stirring was continued till the solution was cooled to near room temperature. Water was added to compensate the lost water volume during the heating process.
To prepare gold-conjugated M-STV and NeutrAvidin, 240 µL of 1% potassium carbonate was added to 30 mL of the colloidal gold suspension and mixed well. Based on the results of a preliminary optimization test, 120-160 µL of proteins (1 mg/mL in water) was added slowly to the gold suspension with stirring. After mixing, the suspension was let sit at room temperature for 10 minutes. Then, 10% bovine serum albumin (BSA, Sigma-Aldrich, Darmstadt, Germany) was added to a final concentration of 0.1% and let sit for 5 minutes at room temperature. The suspension was centrifuged for 30 minutes at 10 000 g. The supernatant was carefully removed by aspiration, and 1.5 mL of 2 mmol/L borax buffer containing 0.1% BSA and 10% sucrose was added. The resuspended colloidal gold was stored at 4°C.
| Preparation of lateral flow rapid test strips
The lateral flow strips for rapid test were designed and assembled flowing the general outlines described as Chiao et al. 22 A 
| Rapid test of serum samples using the test strips
The rapid test was carried out in 2-mL Eppendorf tubes. In general, 
| RE SULTS AND D ISCUSS I ON
| Cloning streptavidin fusion genes and purification of proteins
The coding sequence of streptavidin gene without the signal peptide portion was fused to the malE gene encoding MBP on the pMAL-5cx
vector. HIS-tag was added to the 3'-end of the gene so the recombinant protein could be purified on affinity columns targeting MBP and HIS-tag, respectively. The fusion protein M-STV was first purified through an amylose column, generating the M-STV of about 90%-95% purity, which was subject to a second-step purification on a cobalt resin column to generate about 95%-98% purity ( Figure 1A ).
It was reported that streptavidin fused to a portion of bacterial translational initiation factor IF2 gene increased solubility of streptavidin. 23 To test the effect of fusion of streptavidin with this gene, a portion of the gene encoding amino acids #159-390 was fused inframe to the HIS-tagged stv gene on pET28 to produce the fusion protein IF-STV. Purification of IF-STV using affinity chromatography targeting the HIS-tag resulted in about 90%-95% purity ( Figure 1B ).
| Characterization of recombinant fusion streptavidin by ELISA tests
To test how efficiently the recombinant M-STV and IF-STV fusion proteins bind to biotin, an ELISA was performed using the fusion proteins to coat 96-well plates and measuring the binding of a biotinlabeled mouse monoclonal antibody to the coated fusion proteins. 
| Using recombinant fusion streptavidin in rapid test format
Our goal was to test whether the fusion streptavidin can be used in rapid test to detect specific antibodies or antigens in a biological sample such as testing hepatitis C virus (HCV) infection. For this purpose, we prepared gold nanoparticle suspensions, labeled M-STV, and used it as a signal reporter to detect biotin-conjugated antigen captured on a lateral flow-based rapid test strip. As expected, the To detect anti-HCV antibodies in HCV-infected patient blood, a recombinant HCV protein was constructed and purified. The protein was printed onto the nitrocellulose membrane, which was used to capture anti-HCV antibodies in the serum samples of HCV-infected patients.
A part of the HCV protein was conjugated to biotin and was included in the reaction mixture that also contained the gold-labeled M-STV, To compare the sensitivity of detection between M-STV and
NeutrAvidin, a HCV-positive serum sample was serially diluted with HCV-negative human serum. The gold-labeled NeutrAvidin, generates detectable signal when the HCV serum was diluted up to 100-fold. On the other hand, the gold-labeled M-STV showed an even better detection sensitivity as it was able to generate a clearly visible signal even at 200-fold of serum dilution ( Figure 5A ,B).
Fusion proteins have wide applications in modern biological research. MBP is one of the best studied and most frequently used fusion tags. The MBP moiety facilitates the purification of the target protein. In many cases, it increases the yield of their passenger proteins and helps to enhance the solubility and stability of the fusion partners. [26] [27] [28] In this study, the M-STV was easily purified to over 90% purity by a single-step affinity chromatography and showed great solubility and stability. Moreover, M-STV offers more binding sites for gold labeling while not affecting the binding between the streptavidin moiety and biotin. Possibly, these features of M-STV make it a better detection reporter with higher sensitivity than streptavidin and NeutrAvidin in the rapid test.
Taken together, our results showed that gold-labeled M-STV is a promising detection agent in lateral flow-based rapid tests.
Furthermore, M-STV, as novel signal reporter, has a variety of potential applications in the field of molecular detection. 
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